| H00027 | |
| H number | H00027 |
| Name | Ovarian cancer |
| Description | Ovarian cancer is the sixth most common cancer and the fifth leading cause of cancer-related death among women in developed countries. Approximately 90% of human ovarian cancer arises within the ovarian surface epithelium (OSE), with the rest originating from granulosa cells or, rarely, stroma or germ cells. Ovarian epithelial tumors are divided into mucinous, serous, endometrioid, and clear cell subtypes. Approximately 10% of ovarian cancers arise in women who have inherited mutations in cancer susceptibility genes (BRCA1 or BRCA2). The vast majority of ovarian cancers are sporadic, resulting from the accumulation of genetic damage over a lifetime. Several specific genes involved in ovarian carcinogenesis have been identified, including the p53 tumor suppressor gene and ERBB2 and PIK3CA oncogenes. |
| Category | Cancer |
| Network | - |
| Gene | BRCA1 (germline mutation / deletion) [HSA:672] [KO:K10605] BRCA2 (germline mutation / deletion) [HSA:675] [KO:K08775] MSH2 (germline mutation) [HSA:4436] [KO:K08735] MLH1 (germline mutation) [HSA:4292] [KO:K08734] ERBB2 (amplification / overexpression) [HSA:2064] [KO:K05083] K-ras (mutation) [HSA:3845] [KO:K07827] AKT2 (amplification) [HSA:208] [KO:K04456] PIK3CA (amplification) [HSA:5290] [KO:K00922] c-MYC (overexpression) [HSA:4609] [KO:K04377] p53 (mutation / deletion, overexpression) [HSA:7157] [KO:K04451] CTNNB1 [HSA:1499] [KO:K02105] PRKN [HSA:5071] [KO:K04556] OPCML [HSA:4978] [KO:K06773] AKT1 [HSA:207] [KO:K04456] CDH1 [HSA:999] [KO:K05689] |
| Pathogen | - |
| Env factor | - |
| Carcinogen | - |
| Drug | Cyclophosphamide [DR:D00287] Melphalan [DR:D00369] Thiotepa [DR:D00583] Gemcitabine hydrochloride [DR:D01155] Paclitaxel [DR:D00491] Topotecan hydrochloride [DR:D02168] Doxorubicin hydrochloride [DR:D01275] Bevacizumab [DR:D06409] Cisplatin [DR:D00275] Carboplatin [DR:D01363] Olaparib [DR:D09730] (HRD-positive) Niraparib tosilate hydrate [DR:D11895] (BRCA-mutated) Rucaparib camsylate [DR:D10982] (BRCA-mutated) Altretamine [DR:D02841] Mirvetuximab soravtansine [DR:D10954] (folate receptor alpha positive) |
| Comment | - |
| Other DBs | ICD-11: 2C73 ICD-10: C56 MeSH: D010051 OMIM: 167000 |
| Reference | PMID:15111296 AUTHORS Shih IeM, Kurman RJ. TITLE Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. JOURNAL Am J Pathol 164:1511-8 (2004) DOI:10.1016/S0002-9440(10)63708-X PMID:12886939 AUTHORS Katabuchi H, Okamura H. TITLE Cell biology of human ovarian surface epithelial cells and ovarian carcinogenesis. JOURNAL Med Electron Microsc 36:74-86 (2003) DOI:10.1007/s00795-002-0196-6 PMID:12413930 AUTHORS Wenham RM, Lancaster JM, Berchuck A. TITLE Molecular aspects of ovarian cancer. JOURNAL Best Pract Res Clin Obstet Gynaecol 16:483-97 (2002) DOI:10.1053/beog.2002.0298 PMID:10417756 AUTHORS Wright K, Wilson P, Morland S, Campbell I, Walsh M, Hurst T, Ward B, Cummings M, Chenevix-Trench G TITLE beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. JOURNAL Int J Cancer 82:625-9 (1999) DOI:10.1002/(sici)1097-0215(19990827)82:5<625::aid-ijc1>3.0.co;2-2 PMID:14614460 AUTHORS Denison SR, Wang F, Becker NA, Schule B, Kock N, Phillips LA, Klein C, Smith DI TITLE Alterations in the common fragile site gene Parkin in ovarian and other cancers. JOURNAL Oncogene 22:8370-8 (2003) DOI:10.1038/sj.onc.1207072 PMID:22585860 AUTHORS McKie AB, Vaughan S, Zanini E, Okon IS, Louis L, de Sousa C, Greene MI, Wang Q, Agarwal R, Shaposhnikov D, Wong JL, Gungor H, Janczar S, El-Bahrawy M, Lam EW, Chayen NE, Gabra H TITLE The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer. JOURNAL Cancer Discov 2:156-71 (2012) DOI:10.1158/2159-8290.CD-11-0256 PMID:17611497 AUTHORS Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MH, Blanchard KL, Thomas JE TITLE A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. JOURNAL Nature 448:439-44 (2007) DOI:10.1038/nature05933 PMID:18026186 AUTHORS Blechschmidt K, Sassen S, Schmalfeldt B, Schuster T, Hofler H, Becker KF TITLE The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. JOURNAL Br J Cancer 98:489-95 (2008) DOI:10.1038/sj.bjc.6604115 |